International Clinical Trial: Pucotenlimab Combined with Lenvatinib and eribulin in Patients with Advanced Melanoma Failed in First-Line Therapy, a Single-Arm, Open-Label, Multicenter, Phase II Clinical Study

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500114916) titled 'Pucotenlimab Combined with Lenvatinib and eribulin in Patients with Advanced Melanoma Failed in First-Line Therapy, a Single-Arm, Open-Label, Multicenter, Phase II Clinical Study' on Dec. 18, 2025.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Shanghai Sixth People's Hospital

Condition: Melanoma

Recruitment Status: Not Recruiting

Phase: 0

Date of First Enrollment: 2026-01-01

Target Sample Size: Experimental group:35;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=300882

Published by HT Digital Content Services with perm...